Registry for managing and following up on non-muscle-invasive bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The AFU has established a registry to improve the therapeutic management and follow-up of patients with non-muscle-invasive bladder cancer (NMIBC). This observational study aims to collect representative data from urologists who are members of the AFU, focusing on patients monitored for NMIBC. The study will analyze the effectiveness of current management practices and the role of urinary molecular tests in monitoring these patients. Regular endoscopic examinations and urine cytology are emphasized for detecting tumor recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary test (biomarker) prior to their resection (biopsy) diagnosis or recurrence,
* AND adult (equal to or \> 18 years old),
* AND affiliated with a social security scheme in France,
* AND whose monitoring will be carried out at the recruiting center.

Exclusion Criteria:

* Patient being monitored for a non-urothelial bladder tumor
* Patient refusing follow-up
* Opposition to participation in the study
* Adult protected by law

Where it's running

• Hopital Prive de Provence
  Aix-en-Provence, France Recruiting
• CHU Angers
  Angers, France Recruiting
• Hopital Privé Arras les Bonnettes
  Arras, France Recruiting
• Centre hospitalier Privé Montgradé
  Aubergenville, France Recruiting
• Centre Hospitalier Beauvais Simone Veil
  Beauvais, France Recruiting
• CHU Caen
  Caen, France Recruiting

Study contacts

• Study coordinator: Yann Neuzillet
• Email: registres@afu.fr
• Phone: +33145480609

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMIBC sample collection to test cancer monitoring biomarkers

  This study tests a blood, urine, and tumor tissue collection approach in people with high-risk non-muscle invasive bladder cancer to see if a molecular test can detect residual disease and monitor recurrence.

  Recruiting Natera, Inc. · Austin, Texas · NCT07763197

• Sequential Gemcitabine Plus Docetaxel vs Gemcitabine Plus Mitomycin C for BCG-Unresponsive NMIBC

  This study tests whether adding docetaxel after gemcitabine is better or worse than adding mitomycin C after gemcitabine for people with BCG-unresponsive high-grade non-muscle-invasive bladder cancer.

  Recruiting Phase 2 Blokhin's Russian Cancer Research Center · Moscow, Moscow · NCT07747740

• Is ongoing systemic immunotherapy needed after achieving tumor-free status in very-high-risk NMIBC?

  This study tests whether patients who have become tumor-free after a systemic immunotherapy-based bladder-sparing treatment can safely stop therapy and instead be watched closely.

  Recruiting at 4 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 3 other locations · NCT07625527

• Comparing CT and MRI with VI-RADS for Bladder Cancer Staging

  This study tests how well CT and MRI with VI-RADS can correctly stage bladder cancer before surgery in adults.

  Recruiting Oslo University Hospital · Oslo · NCT07602010

• How bladder microbes and immune signals affect lower urinary tract health

  This project will test whether differences in bladder microbes and immune signals are linked to urinary tract health in adults with and without various urinary conditions.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07494864

• Cretostimogene for BCG‑unresponsive high‑grade non‑muscle‑invasive bladder cancer

  This treatment will test cretostimogene plus n‑dodecyl‑β‑D‑maltoside in adults whose high‑grade non‑muscle‑invasive bladder cancer did not respond to BCG (carcinoma in situ with or without Ta/T1 tumors).

  Recruiting at 14 sites Phase 2 Lepu Biopharma Co., Ltd. · Beijing, Beijing Municipality and 13 other locations · NCT07283835

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.